Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 768.39

+1.7%

11:27 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Felix B who wrote (1998)	1/6/2017 9:34:09 PM
From: Miljenko Zuanic	of 3559

<It boggles my mind that the concept of an Ab to a particular epitope (even if they are different antibodies) is patentable...> Not only to particular epitope (that is too broad and Praluent have no patent issue from it), bat to single aminoacid residue on epitope-point of interaction, that is mind blowing! 8,859,741 1. An isolated monoclonal antibody that binds to PCSK9, wherein the isolated monoclonal antibody binds an epitope on PCSK9 comprising at least one of residues 237 or 238 of SEQ ID NO: 3, and wherein the monoclonal antibody blocks binding of PCSK9 to LDLR. If REGN is not capable of invalidating certain claims in the Repatha patents, it will set cascade of the IP fight all over the bio-sphere. The only one who will benefit from it are Lawyers. Patients (healthcare) will pay for it. Permanent injunctions is irrelevant (but justified), IP right need to be preserved.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next